Dr. Stephanie Alimena, MD

Dr. Alimena practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Dr. Alimena's NPI, 1124559984, was assigned on March 23, 2017. Dr. Alimena graduated from University of Connecticut School of Medicine in 2014. Dr. Alimena holds Massachusetts license 286734.

Dr. Alimena's primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Dr. Alimena's primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Alimena is also affiliated with Massachusetts General Hospital. The medical group on file is Brigham and Women's Hospital. Dmand AI also links Dr. Alimena to 2 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Alimena practices, 4 sites in all. Vendor and product names are available with a free account.

Obstetrics and gynecology is Dr. Alimena's primary specialty in the NPI Registry, under taxonomy code 207V00000X. Dr. Alimena is licensed in Massachusetts.

CMS data shows 118 Medicare services from Dr. Alimena across 6 procedure codes in 2024, for 98 Medicare patients. Medicare paid $10,317 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 98 Medicare patients who saw Dr. Alimena in 2024. The largest group is 65 to 74, with 53 patients. 69% of them have high cholesterol, and 59% have high blood pressure. 20% are also on Medicaid. Their average risk score is 1.16, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Alimena's median patient age at 63, with 99% women.

In 2024, Dr. Alimena wrote 67 Medicare Part D claims for 45 patients. 100% of them were for generic drugs. CMS names the drug for 17 of them, across 1 drug with 11 or more claims each, at $1,154 in total drug cost. In 2023, CMS named 26 claims across 2 drugs.

Dr. Alimena accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Alimena as offering telehealth. CMS counts 27 procedures of removal of the uterus by Dr. Alimena, more than 96% of the clinicians it reports for that procedure.

Dmand AI links 30 papers to Dr. Alimena, published from 2016 to 2025. 2023 was the busiest year, with 7. The most frequent topics are Uterine Cervical Neoplasms, Genital Neoplasms, Female and Patient Reported Outcome Measures. Dr. Alimena has published most often in Gynecol Oncol. Dr. Alimena's most frequent co-authors are Sarah Feldman, MD, Kevin M. Elias, MD and Annekathryn Goodman, MD.

CMS Open Payments shows 2 general payments to Dr. Alimena from 1 drug or device company from 2023 to 2025. Compensation for serving as faculty or as a speaker for a medical education program make up the largest share, 100% of the total. GlaxoSmithKline, LLC. paid the most, $75,045.

Dr. Alimena graduated from University of Connecticut School of Medicine in 2014.